CTOs on the Move

Provident Clinical Research and Consulting

www.providentcrc.com

 
Provident Clinical Research and Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Cerber-Net

Cerber-Net is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comet Therapeutics

Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMETâ„¢) Platform.

MethylGene

MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Project Farma (PF)

Project Farma is a patient-focused global leader in advancing technical operations from ideation through commercialization with a proven track record of planning, building, and maintaining manufacturing facilities, capital expansions, and technical operations for complex biologics and novel modalities. We provide end-to-end services for the entire manufacturing lifecycle for pharmaceutical and biotech companies, universities, hospitals, and government agencies. Project Farma has executed 100+ facility builds, retrofits and expansions, managed 400+ large scale capital projects, industrialized 10+ commercial cell, gene, and novel therapies, and managed $6B+ in technical operations capital investments. One of our core values is giving back. Volunteering at hospitals, supporting life science related fundraisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, not only do we raise awareness of many life-threatening diseases, but we also bring our team and our clients team closer to the actual patients and families that will be impacted by our work. Project Farma is a PerkinElmer company. (https://www.projectfarma.com/)

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.